Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 5/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711086 | 0.86 | KMT2A (0.38) | NR1I2PKMLMNAMAPTMEN1 | |
| SCHEMBL709919 | 0.82 | NR1I2 (0.41) | NR1I2PKMLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL916625 | 0.82 | SLC6A2 (0.39) | NR1I2LMNAMAPTMEN1KMT2A | |
| SCHEMBL916280 | 0.81 | MAPT (0.39) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL916097 | 0.80 | KMT2A (0.39) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL917414 | 0.80 | SLC6A2 (0.35) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3256709 | 0.79 | LMNA (0.37) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL710045 | 0.79 | PDE7A (0.41) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL916726 | 0.79 | KMT2A (0.36) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL917353 | 0.79 | MAPT (0.35) | LMNAMAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124647-B2 | Non-steroidal androgens compounds | N.V. ORGANON (NL) | 2012-02-28 | — | — | US | disclosed |
| US-8124647-B2 | Non-steroidal androgens compounds | N.V. ORGANON (NL) | 2012-02-28 | — | — | US | disclosed |
| US-20110065768-A1 | NON-STEROIDAL ANDROGENS COMPOUNDS | MERCK SHARP & DOHME B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20110065768-A1 | NON-STEROIDAL ANDROGENS COMPOUNDS | MERCK SHARP & DOHME B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-7795280-B2 | Indoles useful in the treatment of androgen-receptor related diseases | N.V. ORGANON (NL) | 2010-09-14 | — | — | US | disclosed |
| US-7795280-B2 | Indoles useful in the treatment of androgen-receptor related diseases | N.V. ORGANON (NL) | 2010-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065768-A1 | NON-STEROIDAL ANDROGENS COMPOUNDS | AR, NR5A1, SHBG | NR1I2 51/4885PKM 3835/4885FFAR4 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.